The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction

(2016) Marco Demaria et al.   Aging-US

Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN

(2015) J. Grisouard et al.   BLOOD

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo

(2014) P. Gallipoli et al.   BLOOD

Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors

(2014) C. Marty et al.   BLOOD

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours

(2014) X Zhang et al.   BRITISH JOURNAL OF CANCER

Should myeloid and lymphoid neoplasms withPCM1-JAK2and other rearrangements ofJAK2be recognized as specific entities?

(2014) Barbara J. Bain et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

(2014) Johanna C. Bendell et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Specific STAT3-Binding Peptide Exerts Antiproliferative Effects and Antitumor Activity by Inhibiting STAT3 Phosphorylation and Signaling

(2014) Daejin Kim et al.   CANCER RESEARCH

HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer

(2014) Kellie S. Rath et al.   CANCER RESEARCH

The targeting of immunosuppressive mechanisms in hematological malignancies

(2014) M H Andersen   LEUKEMIA

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor

(2014) A. J. Brooks et al.   SCIENCE

STAT5A/B Gene Locus Undergoes Amplification during Human Prostate Cancer Progression

(2013) Bassem R. Haddad et al.   AMERICAN JOURNAL OF PATHOLOGY

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Impact of isolated germline JAK2V617I mutation on human hematopoiesis

(2013) A. J. Mead et al.   BLOOD

Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer

(2013) Amir Sonnenblick et al.   BREAST CANCER RESEARCH AND TREATMENT

Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer

(2013) J Kumar et al.   BRITISH JOURNAL OF CANCER

STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion

(2013) Kyung Hwa Cho et al.   CANCER LETTERS

A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer

(2013) Y.H. Xu et al.   EJSO

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

(2013) Z. Kan et al.   GENOME RESEARCH

Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas

(2013) Fang Liu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells

(2013) M R Pawlus et al.   ONCOGENE

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor

(2013) T M Becker et al.   ONCOGENE

AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors

(2013) E. R. Plimack et al.   ONCOLOGIST

The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation

(2013) Daniel J. Gough et al.   PLoS One

Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth

(2013) X. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nuclear Stat5a/b predicts early recurrence and prostate cancer–specific death in patients treated by radical prostatectomy

(2012) Tuomas Mirtti et al.   HUMAN PATHOLOGY

Janus Kinase Deregulation in Leukemia and Lymphoma

(2012) Edwin Chen et al.   IMMUNITY

SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

(2012) Hanna L.M. Koskela et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

(2012) Malabika Sen et al.   Cancer Discovery

Confocal imaging studies cast doubt on nuclear localization of JAK2V617F

(2011) F. Girodon et al.   BLOOD

Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy Failure

(2011) Amy R. Peck et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis

(2010) E. Pectasides et al.   CLINICAL CANCER RESEARCH

Prognostic significance of nuclear pSTAT3 in oral cancer

(2010) Muzafar A. Macha et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial

(2010) F. Monnien et al.   JOURNAL OF CLINICAL PATHOLOGY

STAT3 tyrosine phosphorylation influences survival in glioblastoma

(2010) Peter Birner et al.   JOURNAL OF NEURO-ONCOLOGY

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma

(2009) S Takemoto et al.   BRITISH JOURNAL OF CANCER

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation

(2009) D. J. Gough et al.   SCIENCE

Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression

(2008) E. C. Brantley et al.   CLINICAL CANCER RESEARCH

Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2

(2008) Alexandra Dusa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia

(2008) Elisabetta Flex et al.   JOURNAL OF EXPERIMENTAL MEDICINE